CARsgen Therapeutics Overview
Company Headquarter: Shanghai, China
Founded: 2014
Workforce: ~200
Company Working: CARsgen Therapeutics (CARsgen) is a clinical-stage immune-oncology company focused on the development of CAR-T therapeutics. The company primarily operates in China and the US. The company has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical needs. The company launched several clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma, and CAR-Claudin18.2-T for gastric and pancreatic cancer. CARsgen also has ongoing clinical programs with a humanized CAR-CD19-T trial for leukemia and a fully human CAR-BCMA-T trial for multiple myeloma. CARsgen intends to submit five investigational new drugs (IND) to the National Medical Products Administration (NMPA), China, and 2 INDs to the FDA in 2019.
Strategy
CARSgen aims to offer innovative CAR T-cell therapies for cancer patients worldwide. It is also focused on engaging in strategic partnerships with academic institutes and hospitals to become a preferred partner for CAR T cell therapies
